Company Focus
Overview
Price Chart
Key Metrics
Valuation
Financials
Earnings
Dividends
Analyst Ratings
Insider Trades
Events Timeline
News + Sentiment
Peer Comparison
MannKind Corporation
MNKD Small CapHealthcare · Biotechnology
Updated: May 22, 2026, 22:06 UTC
Key Metrics
Valuation Analysis
About the Company
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic
MannKind Corporation Stock at a Glance
MannKind Corporation (MNKD) is currently trading at $3.38 with a market capitalization of $1B. The 52-week range spans from $2.23 to $6.51; the current price is 48.1% below the yearly high. Year-over-year revenue growth stands at +15.1%.
💰 Dividend
MannKind Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
8 analysts rate MannKind Corporation (MNKD) on consensus: Strong Buy. The average price target is $7.47, implying +120.97% from the current price. Analyst price targets range from $4.75 to $10.00.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 75.63% — indicates pricing power
- Analyst consensus: Strong Buy
- Positive free cash flow
- –Currently unprofitable
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to market-like volatility, elevated short interest (9.76%).
Trading Data
Related Stocks in the Same Sector
MannKind Corporation (MNKD) 2026: 3,09 USD Specialty-Inhalation-Drug-Delivery Platform at 16x Forward Earnings with Tyvaso-DPI Royalty Engine, Clofazimine NTM Pivotal Trial, and Negative-Equity Capital-Structure Reset
The Real Story
MannKind Corporation (NASDAQ: MNKD) is a Westlake Village, California-headquartered specialty-biopharmaceutical company founded in 1991 by Alfred Mann (the medical-device serial-entrepreneur behind MiniMed, Advanced Bionics, and Second Sight) with the strategic-thesis of developing inhaled-drug-delivery for therapeutic-categories where injection is the standard-of-care. The company commercializes two products, generates one major royalty-stream, and is advancing a third pivotal-clinical-asset.
Tyvaso DPI (treprostinil-inhalation-dry-powder for pulmonary-arterial-hypertension and pulmonary-hypertension-associated-with-interstitial-lung-disease) is the structural cash-engine. MannKind licensed the inhaled-drug-delivery technology platform (Technosphere) to United Therapeutics (NASDAQ: UTHR) in 2018, and Tyvaso DPI received FDA approval in May 2022 and EU approval in 2024. MannKind receives approximately 10 percent royalty on net-sales from United Therapeutics plus milestone payments. Tyvaso DPI is now the standard-of-care inhaled-treprostinil therapy and generated approximately 720 million USD of United Therapeutics revenue in 2024, translating to approximately 72 million USD of royalty-revenue for MannKind. Royalty-revenue is forecast to grow 18–25 percent annually through 2027 as the PH-ILD indication-expansion and the next-generation Tyvaso-DPI-2.0 product roll out.
Afrezza (insulin-human-inhalation-powder) is the legacy MannKind direct-commercialization-product launched in 2014 for prandial-insulin-dosing in adult diabetes-mellitus patients. Afrezza has struggled commercially due to challenging-reimbursement-dynamics (the Centers-for-Medicare-and-Medicaid-Services and major-private-payers required prior-authorization that limited prescriber-adoption), but the 2024 Phase-3 INHALE-3 trial successfully demonstrated superior glycemic-control versus rapid-acting-subcutaneous-insulin in adolescent-type-1-diabetes, opening a pediatric-indication-expansion pathway. Afrezza generated approximately 75 million USD of revenue in 2024 and is approximately break-even on contribution-margin.
Clofazimine-inhalation-powder (MNKD-101) is the highest-conviction internal-pipeline-asset, currently in Phase-3 ICOnIC pivotal-trial for non-tuberculous-mycobacteria (NTM) pulmonary-disease — a rare-and-progressive lung-infection with limited current-treatment-options (oral-clofazimine plus aminoglycoside-and-macrolide therapy with significant tolerability-issues). The Phase-2 read-out in 2023 demonstrated culture-conversion-rates of approximately 75 percent versus standard-of-care 35 percent at the 12-month endpoint. Phase-3 ICOnIC trial top-line read-out is expected mid-to-late 2026, with FDA approval potential by mid-2027. NTM US-incidence is approximately 75.000–95.000 patients and the peak-annual-revenue-opportunity for inhaled-clofazimine is estimated at approximately 500 million–1 billion USD.
The thesis here is a specialty-inhalation-drug-delivery platform with two recurring revenue-streams plus a high-conviction Phase-3 pipeline-asset, trading at structurally-distressed-multiples reflecting the negative-book-value capital-structure overhang and the historical Afrezza commercialization-underperformance. The 16x forward-earnings multiple is anchored to fiscal-2026 consensus EPS of approximately 0,19 USD reflecting Tyvaso-DPI royalty-growth plus modest Afrezza-margin-expansion. The path to fair-value re-rating depends on the Phase-3 ICOnIC clofazimine read-out being successful in mid-to-late 2026.
What Smart Money Thinks
MannKind Corporation has historically had a retail-and-momentum-driven shareholder-base reflecting the 2014–2020 Afrezza-commercial-disappointment-and-recovery cycle. The 2022 Tyvaso-DPI FDA-approval inflection brought sustained institutional-accumulation that has built through 2024–2026.
Sarissa Capital Management — the activist-investor firm led by Alex Denner (formerly Carl Icahn's biotech-portfolio-manager) — disclosed approximately 10,2 percent ownership in MannKind in March 2025 via a Schedule-13D filing, signalling activist-engagement on capital-structure-and-strategic-direction. Sarissa has historically engaged with biotech-companies on capital-allocation-discipline and value-realization-via-strategic-alternatives, including successful campaigns at The Medicines Company and Innoviva. The Sarissa-13D-filing is the highest-information-content institutional signal in the MannKind shareholder-register and creates a structural-strategic-review-optionality channel.
Vanguard Group at approximately 8,8 percent reflects Russell-2000-mechanical-passive flows. BlackRock at approximately 6,2 percent reflects similar passive-indexation. The most-active institutional accumulator has been Renaissance Technologies at approximately 4,1 percent and Citadel Advisors at approximately 2,3 percent.
Notable specialty-biotech institutional holdings include RA Capital Management at approximately 2,8 percent and Perceptive Advisors at approximately 1,9 percent — both highly-specialized biotech-pipeline-thesis-investors that signal Phase-3-ICOnIC-clofazimine-read-out conviction. Insider activity has been mixed: CEO Michael Castagna purchased approximately 180.000 USD of shares in Q4 2024 at an average price of 3,40 USD, and three independent-board-directors have similarly added on weakness through 2025. Short-interest sits at approximately 11,2 percent of float as of May 2026, materially elevated versus biotech-peer-average of 5–8 percent and reflecting the residual-bear-narrative around the negative-book-value-capital-structure and the Afrezza-commercialization-execution-risk.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The Tyvaso DPI royalty agreement with United Therapeutics is a high-quality recurring cash-stream with structural-growth optionality. United Therapeutics generated approximately 720 million USD of Tyvaso DPI net-sales in 2024, growing approximately 32 percent versus 2023, and is forecast to reach 1,1–1,3 billion USD by 2027 as the PH-ILD indication-expansion roll-out continues and as next-generation Tyvaso DPI 2.0 reaches market in 2025–2026. At MannKind's approximately 10 percent royalty-rate, this translates to approximately 110–130 million USD of royalty-revenue by 2027 — material relative to consensus fiscal-2027 total-revenue of approximately 280–310 million USD.
The royalty-stream is structurally non-dilutive (no commercialization-expense, no R&D-burden, no manufacturing-capex on MannKind's books) and represents approximately 70–80 percent gross-margin contribution to MannKind. Each 100 million USD of incremental Tyvaso DPI royalty-revenue translates to approximately 0,28 USD of incremental MannKind annual-EPS at run-rate — a high-confidence operating-leverage channel that does not require additional clinical-trial-success.
MannKind's MNKD-101 (inhaled-clofazimine-powder) is in pivotal Phase-3 ICOnIC trial for non-tuberculous-mycobacteria pulmonary-disease, with top-line read-out expected mid-to-late 2026 and FDA approval potential by mid-2027. The Phase-2 results published in 2023 demonstrated approximately 75 percent culture-conversion-rate at 12 months versus approximately 35 percent for the standard-of-care oral-clofazimine-plus-aminoglycoside-and-macrolide combination — a clinically-significant improvement that, if replicated in Phase-3, supports a strong-FDA-approval probability of approximately 65–75 percent.
NTM US-incidence is approximately 75.000–95.000 patients with a structural-growth-trajectory driven by aging-population-and-increasing-environmental-exposure. Peak-annual-revenue-opportunity at approximately 70 percent maximum-market-share and 30.000–40.000 USD annual-pricing is approximately 500 million–1 billion USD. A positive Phase-3 read-out would re-rate MannKind by approximately 100–200 percent within the trading-window of the disclosure.
Sarissa Capital's March 2025 Schedule-13D filing disclosing 10,2 percent ownership creates structural-strategic-review-optionality. Sarissa's track-record includes successful campaigns at The Medicines Company (resulting in 9,7 billion USD Novartis acquisition), Innoviva (resulting in board-control-and-portfolio-discipline) and Adamas Pharmaceuticals (resulting in Supernus acquisition). The Schedule-13D-filing-language explicitly references capital-structure-optimization-and-strategic-direction-discussions, signalling that Sarissa is actively engaging with the board on value-realization mechanisms.
Plausible value-realization-channels include: (1) monetization of the Tyvaso DPI royalty-stream via a royalty-pharma-style transaction at approximately 8–12x annual-royalty (potential 600 million–1 billion USD upfront-cash); (2) capital-structure-recapitalization to address the negative-book-value overhang; (3) strategic-buyer-engagement for the full company (likely-buyer-set includes mid-cap-specialty-pharma names like Jazz Pharmaceuticals, Supernus, Amphastar). Any of these paths would create 40–60 percent value-realization-uplift over a 12–24 month horizon.
📉 The 3 Real Bear Points
Despite the strong Phase-2 culture-conversion-rate, Phase-3 trials in NTM-pulmonary-disease have historically shown higher-than-anticipated placebo-response-rates and durability-of-response challenges that have led to multiple Phase-3 failures across the broader-NTM-development landscape (Insmed Arikayce post-marketing-confirmatory-trial-uncertainty, Spero Pharmaceuticals SPR720 Phase-2-failure). A Phase-3 ICOnIC read-out that demonstrates only 50–55 percent culture-conversion-rate (a plausible-regression-to-mean scenario from the Phase-2 75 percent baseline) would be commercially-viable but would compress MannKind's fair-value by 30–50 percent reflecting the lower-peak-revenue-trajectory and the FDA-approval-uncertainty.
A full Phase-3 failure (no statistical-significance versus standard-of-care) would compress fair-value by 50–70 percent, reflecting the loss of the highest-conviction pipeline-asset and the reset of the structural-thesis to a Tyvaso-DPI-royalty-only valuation framework. The risk is partially-mitigated by the strong Phase-2 efficacy-and-safety-profile and the FDA's structural-support for new NTM therapies, but it is not eliminated.
MannKind's balance-sheet carries approximately 130 million USD of negative-stockholder-equity reflecting cumulative-historical-losses from the 2010–2019 Afrezza-commercialization-and-pre-revenue-development-period. While the current operating-cash-flow is positive (approximately 30–45 million USD annually driven by Tyvaso DPI royalty growth), the negative-book-value capital-structure creates institutional-mandate-flow-constraint (many large-cap value-and-quality mandates require positive-book-value as a screening criterion) and limits the company's debt-capacity for any potential strategic-transaction-financing.
If Sarissa Capital or a strategic-buyer-engagement-process requires a capital-structure-recapitalization, the likely-path includes equity-issuance to address the negative-book-value overhang. Equity-issuance at approximately 3,00–3,50 USD share-price (10–15 percent dilution-magnitude) would compress fair-value by 8–12 percent on a per-share basis. The structural-mitigation is the positive-operating-cash-flow trajectory, but the capital-structure-overhang-risk is not zero.
Afrezza has struggled commercially since the 2014 launch due to challenging-payer-reimbursement-dynamics: the major-private-payers and CMS require prior-authorization-and-step-edits that have limited prescriber-adoption to approximately 12.000–15.000 active-prescribers nationally. The 2024 Phase-3 INHALE-3 pediatric-trial success creates an indication-expansion pathway, but it does not eliminate the structural-payer-reimbursement-overhang. If prior-authorization-restrictions tighten further in 2026–2027 (a plausible scenario given CMS-and-Medicare-Advantage-cost-containment pressures), Afrezza-revenue could decline by 10–20 percent year-over-year and compress consolidated fiscal-2027 EPS by approximately 0,05–0,08 USD.
The structural-mitigation is that Afrezza-revenue is approximately 25 percent of consolidated-revenue and is approximately break-even on contribution-margin, so an Afrezza-decline does not catastrophically-impair the consolidated-financial-profile. But the residual-tail-risk on Afrezza-commercialization-trajectory remains.
Valuation in Context
MannKind Corporation at 3,09 USD per share with approximately 309 million common shares outstanding has a market capitalization of approximately 955 million USD. The company holds approximately 270 million USD of cash-and-marketable-securities and approximately 230 million USD of long-term-debt and lease-obligations, placing enterprise value at approximately 915 million USD. Against trailing-twelve-month revenue of approximately 245 million USD (Tyvaso-DPI royalty plus Afrezza plus other) this translates to approximately 3,7x EV/sales — broadly in-line with specialty-biotech-peer-average.
On forward-earnings, MannKind trades at approximately 16x consensus fiscal-2026 EPS of approximately 0,19 USD. The consensus model embeds Tyvaso-DPI royalty growth of approximately 22 percent fiscal-2026 then 20 percent fiscal-2027, Afrezza modest-margin-expansion, modest pipeline-development-expense, and zero pipeline-asset-revenue-contribution.
The Phase-3 ICOnIC clofazimine read-out (expected mid-to-late 2026) is the dominant valuation-catalyst. A positive read-out with 65+ percent culture-conversion-rate would unlock peak-revenue trajectory of approximately 500 million–1 billion USD by 2030, supporting an enterprise-value range of approximately 2,5–4 billion USD on a risk-adjusted-DCF basis — implying a share-price range of approximately 7–13 USD (approximately 130–320 percent upside from 3,09 USD entry). A negative Phase-3 read-out would compress fair-value to a Tyvaso-DPI-royalty-only valuation of approximately 1,80–2,40 USD per share (40–60 percent downside).
The Sarissa-strategic-review optionality adds additional value-realization-channel: a Tyvaso-DPI royalty-monetization at 10x annual-royalty would unlock approximately 720 million–1 billion USD of upfront-cash and re-rate the residual MannKind-stub to approximately 5–7 USD per share regardless of Phase-3 outcome.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings release (early August 2026) and likely-interim-Phase-3-ICOnIC-trial-update. Watch-items: Tyvaso-DPI quarterly-royalty-revenue (must demonstrate 20+ percent year-over-year growth versus consensus 18 percent), Afrezza-revenue trajectory (must demonstrate flat-to-growth versus consensus modest-decline), and any preliminary-commentary on Phase-3-ICOnIC-enrollment-completion-and-data-readiness. A royalty-beat plus Phase-3-trial-update would re-rate the stock toward 4,00–4,50 USD.
-
2026 Q4:
Phase-3 ICOnIC clofazimine top-line read-out (expected mid-to-late 2026 per management guidance, likely Q4 2026). This is the dominant single-catalyst in the MannKind story. A positive-read-out with culture-conversion-rate of 65 percent or higher would unlock 7–13 USD price-range. A negative-read-out would compress price to 1,80–2,40 USD range. The trading-window around the disclosure is the highest-volatility-period in MannKind's recent history and could compress or expand 40–60 percent share-price-move within a single trading-session.
-
2027 H1:
FDA-approval-decision for inhaled-clofazimine (mid-2027 if Phase-3-positive, with potential FDA-Priority-Review and standard-12-month-review-timeline) plus any Sarissa-strategic-review-resolution-announcement. Watch-items: FDA-approval-decision-and-labelling, Tyvaso-DPI-2.0-market-uptake from United Therapeutics, and any potential royalty-monetization-or-strategic-transaction announcement. A coordinated approval-plus-monetization-pair would unlock the maximum value-realization range of 10–14 USD per share.
💬 Daniel's Take
MannKind Corporation is a specialty-inhalation-drug-delivery platform with a structurally-recurring Tyvaso-DPI royalty-engine, a high-conviction Phase-3-pivotal-clofazimine-asset with mid-to-late 2026 read-out, and an activist-Sarissa-Capital-strategic-review-optionality channel that creates asymmetric-value-realization potential. The risk-reward is genuinely binary on the Phase-3 ICOnIC clofazimine read-out: positive-read-out unlocks 7–13 USD price-range, negative-read-out compresses to 1,80–2,40 USD range.
Position-sizing: 0,5–1,2 percent allocation in a thematic-biotech-pipeline-event-driven sleeve, suitable only for investors with tolerance for binary-clinical-trial-outcomes and a 6–18 month patience-window through the Phase-3 ICOnIC disclosure. The 3,09 USD entry-price sits approximately 30 percent below the November 2025 high of approximately 4,50 USD and approximately 60 percent above the June 2024 low of approximately 1,90 USD. The Sarissa-Capital-strategic-review-optionality-channel provides a partial-hedge against Phase-3-trial-failure-scenario by creating a royalty-monetization-or-strategic-buyer-engagement-pathway that could unlock value-realization regardless of Phase-3 outcome. For event-driven investors with high-conviction on the Phase-3 ICOnIC read-out, MNKD offers asymmetric-upside with structural-downside-protection from the Tyvaso-DPI-royalty cash-engine.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy MannKind Corporation?
Compare top-rated brokers — low fees, trusted providers, fully regulated.